United Therapeutics Corp. (UTHR) - Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for United Therapeutics Corp. for the period ended June 30, 2026. United Therapeutics is a biotechnology company focused on developing and commercializing therapies for chronic and life-threatening conditions, primarily pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company operates as a single reporting segment.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $783.3 million | $798.6 million | $1,564.8 million | $1,593.0 million |
| Net Income | $333.0 million | $309.5 million | $607.9 million | $631.7 million |
| Diluted EPS | $7.27 | $6.41 | $13.07 | $13.02 |
| Operating Income | $330.8 million | $364.5 million | $656.6 million | $747.3 million |
| Operating Margin | 42.2% | 45.6% | 42.0% | 46.9% |
| Cash & Equivalents | $1,803.2 million (as of June 30, 2026) | |||
| Marketable Investments | $2,000.2 million (Total: $1,921.5M debt + $78.7M equity) | |||
| Debt Outstanding | $0 (Credit facility balance is zero) | |||
| Share Repurchases (YTD) | $1.5 billion (via Accelerated Share Repurchase agreements) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 2% year-over-year for both the quarter and the six-month period. This was driven by a 18% decline in Nebulized Tyvaso sales and a 6% decline in Remodulin sales, attributed to competition from generic treprostinil and new branded competitors (e.g., Liquidia's Yutrepia, Merck's Winrevair).
- Tyvaso DPI Growth: Tyvaso DPI revenues increased 4% for the quarter and 6% year-to-date, driven by volume growth and price increases, partially offset by higher gross-to-net deductions.
- Cost of Sales Increase: Cost of sales rose 14% for the quarter and 29% year-to-date. This increase was primarily due to a significant rise in inventory reserve expense ($19.2 million for the quarter; $64.1 million YTD), largely related to estimated losses on a commercial supply agreement for Tyvaso DPI.
- Effective Tax Rate: The effective income tax rate decreased to 12% for the six months ended June 30, 2026, compared to 24% in the prior year, primarily due to increased excess tax benefits from share-based compensation.
- Share Count Reduction: The company executed $1.5 billion in share repurchases in March 2026, significantly reducing the weighted average shares outstanding and supporting EPS growth despite revenue declines.
Guidance, Outlook, and Risks
- Pipeline Progress:
- Nebulized Tyvaso (IPF): Submitted a supplemental NDA (sNDA) to the FDA in June 2026 following successful Phase 3 TETON-1 and TETON-2 studies. Approval is anticipated in the near term.
- Ralinepag: Submitted an NDA in June 2026 for PAH treatment following successful Phase 3 ADVANCE OUTCOMES study results.
- Xenotransplantation: The EXPAND study for the UKidney product is ongoing with the first transplant occurring in Q4 2025. The EXPRESS study for the UHeart product received FDA clearance in May 2026.
- Acquisition: On July 1, 2026, the company acquired Thymmune Therapeutics for an upfront payment of approximately $140 million, with up to $160 million in potential milestone payments. This is expected to be recorded as an asset acquisition in Q3 2026.
- Legal Contingencies:
- Sandoz Litigation: A final judgment was entered in November 2024 ordering the company to pay approximately $61.6 million in damages plus interest. The company has accrued $75.7 million as of June 30, 2026, and is appealing the decision.
- Liquidia Litigation: Ongoing patent infringement and trade secret misappropriation lawsuits regarding Yutrepia and Tyvaso DPI. A trial regarding trade secrets is scheduled for January 2027.
- Boehringer Ingelheim: A new lawsuit filed in July 2026 alleges trade secret misappropriation and "raiding" of sales representatives.
- Regulatory Risks: The company faces pricing pressure from the Inflation Reduction Act (IRA) and potential Most Favored Nation (MFN) pricing initiatives by the Trump administration. Reimbursement for new indications (e.g., IPF) depends on Medicare coverage determinations which may take over a year.
Investor Verification Checklist
- Verify the timeline and probability of FDA approval for Nebulized Tyvaso for IPF and Ralinepag for PAH, given the recent NDA submissions.
- Assess the impact of the $64.1 million inventory reserve expense on future margins and whether the Tyvaso DPI supply agreement losses are recurring.
- Monitor the status of the Sandoz appeal and the potential for additional liability beyond the accrued $75.7 million.
- Review the competitive landscape impact of Yutrepia and Winrevair on the core treprostinil portfolio, specifically the erosion of Nebulized Tyvaso and Remodulin sales.
- Confirm the integration and financial impact of the Thymmune Therapeutics acquisition in the upcoming Q3 2026 report.